Molecular structure of Idarubicin, CAS Number: 58957-92-9
Idarubicin (CAS 58957-92-9)
Alternate Names:
4-Demethoxydaunorubicin
CAS Number:
58957-92-9
Molecular Weight:
497.49
Molecular Formula:
C26H27NO9
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Idarubicin (CAS 58957-92-9) References
- High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. | Low, M., et al. 2013. Intern Med J. 43: 294-7. PMID: 22757980
- Idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma: results of the IDASPHERE phase I trial. | Boulin, M., et al. 2014. Aliment Pharmacol Ther. 39: 1301-13. PMID: 24738629
- Idarubicin-loaded methoxy poly(ethylene glycol)-b-poly(l-lactide-co-glycolide) nanoparticles for enhancing cellular uptake and promoting antileukemia activity. | Liang, B., et al. 2019. Int J Nanomedicine. 14: 543-556. PMID: 30666113
- Idarubicin Stimulates Cell Cycle- and TET2-Dependent Oxidation of DNA 5-Methylcytosine in Cancer Cells. | Zhong, S., et al. 2019. Chem Res Toxicol. 32: 861-868. PMID: 30816036
- Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation. | Adige, S., et al. 2019. Cancer Chemother Pharmacol. 83: 1105-1112. PMID: 30968179
- Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. | Guiu, B., et al. 2019. Radiology. 291: 801-808. PMID: 31038408
- Insights into idarubicin antimicrobial activity against methicillin-resistant Staphylococcus aureus. | She, P., et al. 2020. Virulence. 11: 636-651. PMID: 32423280
- Idarubicin, an Anthracycline, Induces Oxidative DNA Damage in the Presence of Copper (II). | Mizutani, H., et al. 2020. Anticancer Res. 40: 5399-5404. PMID: 32988859
- Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014). | Zhang, Y., et al. 2022. Am J Hematol. 97: 43-51. PMID: 34687467
- Idarubicin-induced oxidative stress and apoptosis in cardiomyocytes: An in vitro molecular approach. | Zhang, Y., et al. 2021. Hum Exp Toxicol. 40: S553-S562. PMID: 34787021
Inhibitor of:
FIGNL2, HL60 Antigen, Nop5, Placental RNase inhibitor, SSBP2, Sval1, ZBTB8B, ZFF29, ZFP108, and ZFP109.Activator of:
granzyme D, Top3, and Topo II.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Idarubicin, 10 mg | sc-507346 | 10 mg | $180.00 |